Profile data is unavailable for this security.
About the company
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
- Revenue in USD (TTM)0.00
- Net income in USD-37.38m
- Incorporated2017
- Employees52.00
- LocationBiomx Inc22 Einstein St., Floor 4NESS-ZIONA 7414003IsraelISR
- Phone+972 723942377
- Fax+1 8 002535177
- Websitehttps://www.biomx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synlogic Inc | 0.00 | -3.23m | 7.78m | 1.00 | -- | 0.7535 | -- | -- | -0.2625 | -0.2625 | 0.00 | 0.8826 | 0.00 | -- | -- | 0.00 | -17.30 | -44.41 | -27.54 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.87m | 12.00 | -- | 0.3279 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 8.02m | -- | -- | 0.5614 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Biomx Inc | 0.00 | -37.38m | 8.59m | 52.00 | -- | -- | -- | -- | -30.62 | -30.62 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -86.77 | -48.34 | -103.85 | -57.24 | -- | -- | -- | -- | -- | -57.02 | 0.00 | -- | -- | -- | 32.26 | -- | -53.03 | -- |
| StimCell Enegetics Inc | 0.00 | -935.22k | 8.66m | 0.00 | -- | -- | -- | -- | -0.0461 | -0.0461 | 0.00 | -0.0738 | 0.00 | -- | -- | -- | -2,062.23 | -844.03 | -- | -- | -- | -- | -- | -18,037.46 | -- | -17.22 | -- | -- | -- | -- | -297.42 | -- | -- | -- |
| BioVie Inc | 0.00 | -17.48m | 8.68m | 13.00 | -- | 0.4501 | -- | -- | -5.13 | -5.13 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -72.35 | -260.69 | -79.73 | -454.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.73 | -- | -- | -- |
| Pulmatrix Inc | 3.00k | -6.22m | 8.69m | 2.00 | -- | 1.84 | -- | 2,897.48 | -1.70 | -1.70 | 0.0008 | 1.30 | 0.0004 | -- | -- | 1,500.00 | -75.43 | -42.08 | -79.47 | -49.93 | -- | -- | -207,333.30 | -210.36 | -- | -- | 0.00 | -- | 6.96 | -0.2644 | 32.31 | -- | 46.99 | -- |
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 8.72m | 6.00 | -- | 0.6644 | -- | 8,716.65 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Edesa Biotech Inc | 0.00 | -7.19m | 8.92m | 17.00 | -- | 2.39 | -- | -- | -1.35 | -1.35 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -82.86 | -103.16 | -99.57 | -123.95 | -- | -- | -- | -- | -- | -138.68 | 0.00 | -- | -- | -- | -16.46 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -27.16m | 9.22m | 7.00 | -- | 5.88 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Biomx Inc's reporting currency: US Dollar USD
19.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 30 Sep 2025 | 131.23k | 8.60% |
| Alyeska Investment Group LPas of 30 Sep 2025 | 83.72k | 5.48% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2025 | 22.63k | 1.48% |
| DAFNA Capital Management LLCas of 30 Sep 2025 | 21.11k | 1.38% |
| Ikarian Capital LLCas of 30 Sep 2025 | 20.68k | 1.36% |
| Citadel Securities LLCas of 30 Sep 2025 | 8.52k | 0.56% |
| Boothbay Fund Management LLCas of 30 Sep 2025 | 5.50k | 0.36% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 5.39k | 0.35% |
| Adar1 Capital Management LLCas of 30 Sep 2025 | 4.09k | 0.27% |
| UBS Securities LLCas of 31 Dec 2025 | 2.15k | 0.14% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
